Fig. 1

α-mangostin inhibits RANKL‐induced osteoclastogenesis in vitro. A The molecular structure of α-mangostin comes from the official website of sigma-aldrich. B BMMs were treated with different concentrations of α-mangostin for 48 h or 96 h, and viability of BMMs was measured by CCK-8 assay, N = 3. C BMMs were treated with M‐CSF (25 ng/mL) and RANKL (50 ng/mL) in the presence pf the indicated α-mangostin concentrations for 5 days. Cells were then stained for TRAP activity and were photographed. D The number and area of TRAP-positive cells were analyzed, N = 3. E BMMs were stimulated with M‐CSF and RANKL for 5 days, and 2 μmol/L α-mangostin was added at different stages. Scale bars:200 µm (upper layer of C, E), 500 µm (Lower layer of C, E). F The number and area of TRAP-positive cells were analyzed, N = 3. Data are presented as mean ± SD. **P < 0.01, ***P < 0.001, compared with the controls